Concepedia

Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure–activity relationship, computer modeling, optimization, and identification of highly potent antagonists

Blaise Lippa, Joel Morris, Matthew S. Corbett, Tricia A. Kwan, Mark C. Noe, Sheri L. Snow, Thomas G. Gant, Melchiorra Mangiaracina, Heather A. Coffey, Barbara A. Foster,

Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · 12 references

DOIFull text

Open access

Concepts

References

12

An Improved Catalyst System for Aromatic Carbon−Nitrogen Bond Formation:  The Possible Involvement of Bis(Phosphine) Palladium Complexes as Key Intermediates

John P. Wolfe, Seble Wagaw, Stephen L. Buchwald · Journal of the American Chemical Society · 1996 · 603 citations

, , +12

Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles

Edgar R. Wood, Lee F. Kuyper, Kimberly G. Petrov et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 134 citations · Full text

, , +12

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth et al. · PubMed · 2003 · 128 citations

, , +16

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

Daniel J. George, Craig A. Dionne, Jacques Jani et al. · PubMed · 1999 · 126 citations

, , +17

Rational basis for Trk inhibition therapy for prostate cancer

Ashani T. Weeraratna, Julia T. Arnold, Dan George et al. · The Prostate · 2000 · 116 citations

, , +11